Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the anticardiolipin antibody (ACA) in a series of patients with cerebral infarction without
systemic lupus erythematosus
(
SLA
). Clinical and laboratory data were assessed from a series of 250 non-
SLE
patients with cerebral infarction who visited our clinic from 1988 to 1990. The concentration of anticardiolipin IgG antibody was measured by an enzyme-linked immunosorbent assay technique. An elevated ACA level was defined as one which was greater than 3 standard deviations above the mean level for normal controls. We examined the CT findings and risk factors for
stroke
such as hypertension, diabetes mellitus, hyperlipidemia and cardiac disease. Laboratory data such as the platelet count, the presence of
lupus
anticoagulant and a biologic false-positive test for syphilis were also investigated. Among the 250 patients with infarction, IgG ACA was detected in 22 (8.8%). There was no significant difference in incidence of ACA between the patients with cerebral thrombosis and those with cerebral embolism. On CT scan, multiple cerebral infarcts were noted in 18 of the 22 patients. As regards the location of the infarct, the cerebral cortex together with the basal ganglia was more common than isolated lesions of the cortex or basal ganglia. Concerning the risk factors for
stroke
, hypertension was noted in 12, diabetes mellitus in 2, hyperlipidemia in 2 and cardiac disease in 2.
Lupus
anticoagulant and thrombocytopenia were not detected in any of the cases. A biologic false-positive test for syphilis was observed in one case. Dementia was present in 12 of the 22 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Anticardiolipin antibody in cerebral infarction]. 191 23
Anticardiolipin antibodies (aCL), one of a group of antiphospholipid antibodies which include the
lupus
anticoagulant (LA), may occur in association with
systemic lupus erythematosus
(
SLE
) and are less commonly detected in other diseases. We retrospectively reviewed the clinical and immunological features of 39 consecutive patients with abnormal aCL identified by one laboratory, to examine the spectrum of neurological disease in those patients without
SLE
. Fourteen patients in this category are described, 6 of whom did not have evidence of LA. All but 1 presented with neurological symptoms.
Stroke
and migraine dominated the clinical presentation, but many patients had features to suggest the presence of a hypercoagulable state. This study lends support to the concept of a primary antiphospholipid syndrome.
...
PMID:Neurological disease associated with anticardiolipin antibodies in patients without systemic lupus erythematosus: clinical and immunological features. 196 May 45
In a 2-year prospective study of 146 patients with cerebral ischemia, we compared vascular risk factors for
stroke
with clinical and laboratory findings, particularly antiphospholipid antibodies. Ten patients (6.8%) were positive for at least one antiphospholipid antibody; one patient had
systemic lupus erythematosus
, one had rheumatoid arthritis, and the remaining eight fulfilled criteria for the diagnosis of primary antiphospholipid syndrome. These patients were predominantly male, not necessarily young, and 50% of them did not have any other vascular risk factors; there were no significant clinical or paraclinical differences between these patients and those without antiphospholipid antibodies. Outcome in the 10 patients was good, and platelet antiaggregating drugs proved to be useful in preventing further cerebrovascular ischemic events in our patients.
Stroke
1991 Jun
PMID:Antiphospholipid antibodies in cerebral ischemia. 205 74
We describe 2 patients with
systemic lupus erythematosus
(
SLE
) who developed an acute psychosis and a
cerebrovascular accident
after pulse methylprednisolone therapy. A literature review revealed 8 additional patients with
SLE
with acute central nervous system complications after pulse therapy.
...
PMID:Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosus. 208 49
Antiphospholipid antibodies (APA) have been reported to be associated with thrombosis in
systemic lupus erythematosus
(
SLE
) and in many other clinical groups. However, although these antibodies have been identified in a substantial number of patients infected with the human immunodeficiency virus (HIV), in this case an association with thrombosis has not been evident. We describe a patient with HIV infection who had anticardiolipin antibodies (ACA) but no
lupus
anticoagulant (LA) who had recurrent transient ischaemic attacks (TIAs) and a mild
stroke
.
...
PMID:Multiple transient ischaemic attacks and a mild thrombotic stroke in a HIV-positive patient with anticardiolipin antibodies. 210 18
Lupus
anticoagulant and antiphospholipid antibodies are associated with thromboembolic phenomena in individuals both with and without
systemic lupus erythematosus
. A 32-year-old woman (the index case) with
lupus
anticoagulant, multiple cerebrovascular events, and a family history of premature
stroke
raised the possibility of a familial diathesis. Histories or interviews, examinations, and blood tests were obtained for 23 members of four generations of her family. Four individuals had suffered strokes and three more had suffered neurologic symptoms. Two living individuals who had suffered strokes, two individuals with neurologic symptoms, and five asymptomatic individuals had antiphospholipid activity in their blood. In addition, a cousin of the index case was found to have
systemic lupus erythematosus
and antiphospholipid activity. Elevated concentrations of von Willebrand factor antigen were found associated with some positive
lupus
anticoagulant assays, the highest concentrations in the two individuals with
stroke
. The characteristic presentation of the index case and her good response to treatment suggests that further studies of families in whom antiphospholipid antibodies may represent a risk factor for
stroke
is worthwhile.
Stroke
1990 Jan
PMID:Premature stroke in a family with lupus anticoagulant and antiphospholipid antibodies. 210 44
The case of a 13 year old girl with renal artery thrombosis and hypertension is described. A
cerebrovascular accident
and a probable occlusion of the superior mesenteric artery also occurred. Very high levels of '
lupus
anticoagulant', anticardiolipin antibodies as well as false positive Venereal Disease Research Laboratory tests were repeatedly shown. Moreover, the patient fulfilled at least four classification criteria for
systemic lupus erythematosus
, but only a slight positivity for antinucleolar antibodies was present. The striking relation between antiphospholipid antibody levels and clinical events and the treatment of this complex syndrome are discussed.
...
PMID:Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. 210 19
The importance of a prothrombotic state as a cause of ischemic
stroke
in young adults is ill defined. We examined 46 unselected patients under age 50 years with cerebral ischemia for anticardiolipin antibody (aCL) and
lupus
anticoagulants (LA), over a 3-year-period. Age- and sex-matched patients with other neurologic diseases served as a noncerebral ischemia comparison group to test whether (1)
stroke
/transient ischemic attacks (TIA) in young people is associated with aCL and/or LA, and (2) their presence is specific to cerebral ischemia. In the
stroke
/TIA group, 21 patients had aCL or LA and 25 had neither, whereas in the control group, 2 patients had aCL and 24 had neither. Equal numbers of
stroke
/TIA patients with and without antiphospholipid antibodies (aPL) had other
stroke
risk factors. Patients with aPL and cerebral ischemia, however, had a more frequent history of multiple events than those without them. These antibodies occur with undue frequency in young patients with
stroke
/TIA and are not associated with a concurrent diagnosis of systemic
lupus
in most cases. A coexistent aPL-associated prothrombotic state may be a key determinant of whether patients with atherosclerosis, mitral valve prolapse, or other structural lesions experience recurrent ischemia.
...
PMID:Antiphospholipid antibodies and cerebral ischemia in young people. 211 4
The case of a young, male patient hospitalized for investigation of a
cerebral vascular accident
is reported. The investigations led to the diagnosis of
disseminated lupus erythematosus
associated with the presence of antiphospholipid antibodies (
lupus
circulating anticoagulant and anticardiolipin antibody). The authors discuss certain notions relating to antiphospholipid antibodies and the thromboembolic, particularly neurological, manifestations thereof.
...
PMID:[Multiple cerebral infarcts in a young man]. 212 Sep 5
The frequency of "Lupus anticoagulant" (LA), was studied in 51 patients with
systemic lupus erythematosus
(
SLE
), 15 patients with chronic immune thrombocytopenic purpura (ITP) and 3 other patients with prolonged partial thromboplastin time (PTT), two of which had suffered episodes of
CVA
, and the other had a diagnosis of Paroxysmal Nocturnal Hemoglobinuria.
Lupus
anticoagulant was determined in each patient by the plasma recalcification time and the Russell's viper venom clotting time. Eight patients with
SLE
, (15.6%) 6 with chronic ITP (40%) and the three patients with prolonged PTT were positive for LA. All patients with LA were female, whose ages ranged from 19 to 59 years, and all except two patients were under steroid therapy. Thrombocytopenia was the most frequent manifestation in the patients with LA, followed by recurrent fetal death and thrombosis. Only the patients with ITP had hemorrhagic complications and one of them also had
CVA
in one occasion. The immunosupressory therapy may have played a role in diminishing the frequency of LA in the patients studied.
...
PMID:[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]. 212 14
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>